Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 4.5% – Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares were up 4.5% on Thursday . The company traded as high as $22.36 and last traded at $22.22. Approximately 122,911 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 230,251 shares. The stock had previously closed at $21.25.

Analyst Upgrades and Downgrades

ELVN has been the topic of several research analyst reports. Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and a consensus target price of $38.25.

Enliven Therapeutics Stock Performance

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -11.29 and a beta of 1.04. The business’s 50 day simple moving average is $21.89 and its 200-day simple moving average is $23.92.

Insiders Place Their Bets

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now owns 329,977 shares of the company’s stock, valued at $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $265,330. This represents a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,117 shares of company stock valued at $949,435 in the last three months. Insiders own 29.20% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC grew its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics during the 4th quarter valued at $97,000. BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics in the 4th quarter valued at $112,000. ExodusPoint Capital Management LP acquired a new stake in Enliven Therapeutics in the 4th quarter worth $200,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Enliven Therapeutics during the 4th quarter worth about $228,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.